These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 28662279

  • 1. Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial.
    Krishnan A, Teixeira-Pinto A, Chan D, Chakera A, Dogra G, Boudville N, Irish A, Morgan K, Phillips J, Wong G, Lim WH.
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28662279
    [Abstract] [Full Text] [Related]

  • 2. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
    Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, Ackermann D, Guba M, Jacobi J, Hauser IA, Stahl R, Reinke P, Rath T, Veit J, Mehrabi A, Porstner M, Budde K, HERAKLES Study Group.
    Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
    [Abstract] [Full Text] [Related]

  • 3. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D, Silva HT, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, Wang Z, Zibari GB, Shihab F, Kim YS.
    Transplantation; 2013 Apr 15; 95(7):933-42. PubMed ID: 23422495
    [Abstract] [Full Text] [Related]

  • 4. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Apr 15; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 5. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
    Taber DJ, Chokkalingam A, Su Z, Self S, Miller D, Srinivas T.
    Clin Transplant; 2019 Oct 15; 33(10):e13679. PubMed ID: 31365151
    [Abstract] [Full Text] [Related]

  • 6. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
    Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, Wüthrich RP, Mühlfeld A, Heller K, Porstner M, Veit J, Paulus EM, Witzke O, ZEUS Study Investigators.
    Am J Transplant; 2015 Jan 15; 15(1):119-28. PubMed ID: 25521535
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
    Carmellini M, Garcia V, Wang Z, Vergara M, Russ G.
    J Nephrol; 2015 Oct 15; 28(5):633-9. PubMed ID: 25708913
    [Abstract] [Full Text] [Related]

  • 8. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F, TRANSFORM Investigators.
    J Am Soc Nephrol; 2018 Jul 15; 29(7):1979-1991. PubMed ID: 29752413
    [Abstract] [Full Text] [Related]

  • 9. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials.
    Cooper M, Wiseman AC, Zibari G, McCague K, Kim Y, Geissler F, Nashan B.
    Clin Transplant; 2013 Jul 15; 27(6):E625-35. PubMed ID: 24033455
    [Abstract] [Full Text] [Related]

  • 10. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial.
    Murbraech K, Massey R, Undset LH, Midtvedt K, Holdaas H, Aakhus S.
    Clin Transplant; 2015 Aug 15; 29(8):678-84. PubMed ID: 25982053
    [Abstract] [Full Text] [Related]

  • 11. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J, TRANSFORM investigators.
    Am J Transplant; 2019 Nov 15; 19(11):3018-3034. PubMed ID: 31152476
    [Abstract] [Full Text] [Related]

  • 12. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
    de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M, ELEVATE Study Group.
    Am J Transplant; 2017 Jul 15; 17(7):1853-1867. PubMed ID: 28027625
    [Abstract] [Full Text] [Related]

  • 13. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
    Sommerer C, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Wolters HH, Suwelack B, Klehr HU, Hauser IA, Stangl M, Nadalin S, Dürr M, Porstner M, May C, Wimmer P, Witzke O, Lehner F.
    Clin Nephrol; 2016 Apr 15; 85(4):215-25. PubMed ID: 26932178
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporine versus everolimus: effects on the glomerulus.
    Baas MC, Kers J, Florquin S, de Fijter JW, van der Heide JJ, van den Bergh Weerman MA, ten Berge IJ, Bemelman FJ.
    Clin Transplant; 2013 Apr 15; 27(4):535-40. PubMed ID: 23795805
    [Abstract] [Full Text] [Related]

  • 15. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
    Cruzado JM, Pascual J, Sánchez-Fructuoso A, Serón D, Díaz JM, Rengel M, Oppenheimer F, Hernández D, Paravisini A, Saval N, Morales JM, Evita Study Group.
    Transpl Int; 2016 Dec 15; 29(12):1317-1328. PubMed ID: 27648523
    [Abstract] [Full Text] [Related]

  • 16. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
    Tönshoff B, Ettenger R, Dello Strologo L, Marks SD, Pape L, Tedesco-Silva H, Bjerre A, Christian M, Meier M, Martzloff ED, Rauer B, Ng J, Lopez P.
    Am J Transplant; 2019 Mar 15; 19(3):811-822. PubMed ID: 30125462
    [Abstract] [Full Text] [Related]

  • 17. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M.
    J Nephrol; 2011 Mar 15; 24(5):613-8. PubMed ID: 21240873
    [Abstract] [Full Text] [Related]

  • 18. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
    Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE investigators.
    Am J Transplant; 2016 Apr 15; 16(4):1238-47. PubMed ID: 26820618
    [Abstract] [Full Text] [Related]

  • 19. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
    Budde K, Zeier M, Witzke O, Arns W, Lehner F, Guba M, Jacobi J, Kliem V, Reinke P, Hauser IA, Vogt B, Stahl R, Rath T, Duerr M, Paulus EM, May C, Porstner M, Sommerer C, HERAKLES Study Group.
    Nephrol Dial Transplant; 2017 Jun 01; 32(6):1060-1070. PubMed ID: 28605781
    [Abstract] [Full Text] [Related]

  • 20. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Jun 01; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.